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Introduction
Collagens are abundant, ubiquitous protein constituents of the
extracellular matrix (ECM). They play essential roles in wound
healing and the growth with differentiation and morphogenesis of
tissues and in controlling vital cellular functions such as migration,
adhesion and signalling (Leitinger and Hohenester, 2007). The
coordinated synthesis, deposition and degradation of collagens is
essential for physiological tissue homeostasis, and its deregulation
underpins inflammatory and fibrotic diseases and tumour growth
and metastasis (Perez-Tamayo, 1978).
Collagen remodelling occurs via two distinct pathways. The
first pathway is extracellular and/or pericellular collagen
degradation by matrix metalloproteinases (MMPs), of which,
membrane-anchored membrane-type-1 matrix metalloproteinase
(MT1-MMP, also known as MMP-14), is a key collagenolysin
(Holmbeck et al., 1999; Sato et al., 1994; Zhou et al., 2000). MT1-
MMP directly degrades ECM proteins including collagens I-IV
and is also a potent activator of latent proMMP-2, which in the
active form degrades gelatin and collagens I and IV (Butler et al.,
1998; Itoh and Seiki, 2006; Strongin et al., 1995). In vivo, MT1-
MMP collagenolysis is essential for post-natal connective tissue
remodelling (Holmbeck et al., 1999; Zhou et al., 2000) and for
tumour formation, invasion and metastasis (Hotary et al., 2003;
Sabeh et al., 2004; Seiki et al., 2003; Szabova et al., 2008; Wolf
et al., 2007). MT1-MMP activity is stringently regulated by both
endogenous inhibitors, TIMPs (tissue inhibitors of
metalloproteinase) (Brew et al., 2000), and by transcriptional and
post-translational mechanisms, including autocatalytic processing
(Lehti et al., 1998; Rozanov et al., 2001).
The second collagen degradation pathway requires specific
binding and cellular uptake of collagen for delivery to intracellular
degradative compartments. This occurs via a2b1-integrin-mediated
phagoctyic uptake, which is considered the primary pathway in the
remodelling of adult tissues (Everts et al., 1996). Recently, a novel
collagen-binding and collagen-internalisation receptor, Endo180
(endocytic receptor 180) was identified. Endo180 is a constitutively
recycling receptor that binds collagens and internalises them via
clathrin-coated pits into early endosomes for lysosomal degradation
(Engelholm et al., 2003; Kjoller et al., 2004; Wienke et al., 2003).
Moreover, recent in vivo studies identified the importance of
Endo180 in ECM remodelling during post-natal bone development
(Wagenaar-Miller et al., 2007) and in tumour progression (Curino et
al., 2005; Wienke et al., 2007).
Despite the established importance of both these pathways, the
relationship between them is virtually unexplored. Studies to date
have focused on how MT1-MMP-mediated limited fragmentation
of collagen might influence uptake by Endo180 (Madsen et al.,
2007; Wagenaar-Miller et al., 2007). By contrast, here we have
explored whether Endo180 can regulate protease activity and thus
direct pericellular collagen proteolysis.
The molecular interactions leading to organised, controlled
extracellular matrix degradation are of central importance
during growth, development and tissue repair, and when
deregulated contribute to disease processes including cancer
cell invasion. There are two major pathways for collagen
degradation: one dependent on secreted and membrane-
bound collagenases, the other on receptor-mediated collagen
internalisation and intracellular processing. Despite the
established importance of both pathways, the functional
interaction between them is largely unknown. We demonstrate
here, that the collagen internalisation receptor Endo180 (also
known as CD280, uPARAP, MRC2) is a novel regulator of
membrane-bound matrix metalloproteinase (MT1-MMP)
activity, MT1-MMP-dependent MMP-2 activation and
urokinase plasminogen activator (uPA) activity. We show close
correlation between Endo180 expression, collagen
accumulation and regulation of MT1-MMP cell-surface
localisation and activity. We directly demonstrate, using
collagen inhibition studies and non-collagen-binding mutants
of Endo180, that the molecular mechanism underlying this
regulation is the ability of Endo180 to bind and/or internalise
collagens, rather than by acting as an interaction partner for
pro-uPA and its receptor uPAR. These studies strongly support
a functional interaction between two distinct collagen
degradation pathways, define a novel mechanism regulating
MT1-MMP activity and might have important implications
for organised collagen clearance in the pericellular
environment.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/122/22/4042/DC1
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Results and Discussion
Endo180 regulates protease activity
To investigate whether Endo180 is involved in regulating protease
activity, HT1080 human fibrosarcoma cells were treated with
Endo180-targeting siRNA oligonucleotides (Fig. 1A). Initially,
MMP-2 activity was examined directly by monitoring the activation
of proMMP-2 using gelatin zymography.
A striking increase in MMP-2 activity was observed following
Endo180 depletion, evidenced by substantially increased conversion
of proMMP-2 to the active enzyme in both cell lysates and
conditioned media (Fig. 1B). This increased protease activity was
not an off-target effect as an Endo180 siRNA SMARTpool and three
independent Endo180-targeting oligonucleotides all effectively
decreased Endo180 expression (Fig. 1A) and produced an identical
phenotype (Fig. 1B). Moreover, this phenotype was rescued by
expression of murine wild-type Endo180 (shown below).
Additionally, Endo180 depletion did not affect proMMP-9 activation
(supplementary material Fig. S1). Finally, proMMP-2 activation
cannot be attributed simply to downregulation of an endocytic
receptor because siRNA-induced downregulation of transferrin
receptor had no effect on proMMP-2 activation (supplementary
material Fig. S2).
Endo180 can interact with pro-urokinase plasminogen activator
(pro-uPA) bound to its GPI-anchored receptor, uPAR (Behrendt,
2004; Behrendt et al., 2000). Pro-uPA binds uPAR, allowing for
conversion to active uPA, and because both uPA and plasmin
(generated from plasminogen by uPA) can activate proMMP-2
directly and indirectly via MT1-MMP (Kazes et al., 1998; Keski-
Oja et al., 1992; Mazzieri et al., 1997; Monea et al., 2002) we
considered the Endo180-uPAR-uPA system to be a potential
regulatory component involved in MMP-2 activation. Consistently,
a significant increase in uPA activity was observed in the conditioned
media of Endo180-depleted cells (Fig. 1C,D). However, treatment
with specific uPA inhibitors or uPA siRNA at concentrations that
significantly reduced uPA activity (Fig. 1E) failed to inhibit
proMMP-2 activation following Endo180 downregulation (Fig. 1F,
supplementary material Fig. S3A,B). Likewise, the plasmin inhibitor
aprotinin was ineffective (not shown). Thus, regulation of MMP-
2 activity by Endo180 is independent of uPA-uPAR and the
plasminogen cascade. Conversely, the broad-spectrum MMP
Fig. 1. Targeted depletion of Endo180 increases
protease activity. (A-D)Endo180 siRNAs (single
oligonucleotides targeting three distinct
sequences or SMARTpool oligonucleotides) or
control siRNAs were transfected into HT1080
cells. Untreated and mock-transfected cells were
used for comparison. After 24 hours serum-free
media was added for 48 hours. (A)Lysates were
immunoblotted for Endo180 or a-tubulin.
(B)Lysates and conditioned media were
analysed for MMP-2 activation (gelatin
zymograms). Arrows indicate pro- (72 kDa) and
active (62 kDa) MMP-2. Partially activated
(intermediate) MMP-2 migrates at 62 kDa.
MMP-2 activation was quantified by
densitometry and expressed as a percentage of
total MMP-2 (pro+intermediate+active).
*P<0.05 (n3), **P<0.001 (n9) compared with
control siRNA. (C)Casein zymograph showing
uPA activity in conditioned media.
Quantification of uPA bands in arbitrary units;
*P<0.05 (n4). (D)Plasminogen activator
activity in conditioned media (U/ml, n3) was
assayed using Spectrozyme PL chromogenic
plasmin substrate. *P<0.01. (E)Endo180-
siRNA-transfected cells were left untreated or
treated with uPA inhibitors [PAI-1 (500 ng/ml),
anti-uPA neutralising mAb (20mg/ml), amiloride
(25mg/ml)] or alternatively were co-transfected
with either control siRNA or siRNA targeting
uPA and cultured as above. Plasminogen
activator activity in conditioned media was
analysed as in D (n3) and is presented relative
to non-co-transfected, untreated Endo180-
siRNA-transfected cells. (F)Control- or
Endo180-siRNA-transfected cells were untreated
(–) or treated with uPA inhibitors or with the
MMP inhibitor GM6001 (5mM) and cultured as
above. MMP-2 activation was analysed in
conditioned media. To compare responses
between treatments, data were quantified as the
ratio of proMMP-2 activity in Endo180 siRNA
cells to that in mock-transfected cells for each
treatment. Controls were the ratio of proMMP-2
activity in control siRNA cells to that in mock-
transfected cells; **P<0.001 compared to
appropriate control (n6-8).
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inhibitor GM6001 completely abrogated proMMP-2 activation
(Fig. 1F), indicating a requirement for MMP activity and suggesting
that regulation of MMP-2 activity by Endo180 is most probably
MT1-MMP-dependent.
To confirm that increased MMP-2 activation occurred as a
consequence of the ability of Endo180 to regulate MT1-MMP
activity, cells were treated with siRNAs against Endo180 and MT1-
MMP. Two separate MT1-MMP siRNAs substantially reduced MT1-
MMP expression (Fig. 2A) and prevented the small, basal level of
proMMP-2 activation (Fig. 2B) (Ueda et al., 2003). Other MT-MMP
family members besides MT1-MMP can activate proMMP-2.
Quantitative RT-PCR confirmed that the MT1-MMP siRNAs only
targeted MT1-MMP, and not any other MT-MMPs (MT2-MMP to
MT6-MMP, not shown). Endo180 siRNA treatment alone or in
conjunction with control MT1-MMP siRNA, again resulted in
pronounced activation of MMP-2 (Fig. 2B,C). Conversely,
activation of MMP-2 was completely abrogated when cells were
Journal of Cell Science 122 (22)
treated with both Endo180- and MT1-MMP–siRNA-targeting
oligonucleotides (Fig. 2B,C), in agreement with data obtained using
the MMP inhibitor GM6001 (Fig. 1F). Moreover, as increased uPA
activity following Endo180 downregulation is significantly reduced
when MT1-MMP is also downregulated (supplementary material
Fig. S3C), it is probable that regulation of uPA activity occurs as
a secondary consequence of increased MT1-MMP and MMP-2
activity (Prager et al., 2004).
Endo180 regulates the autolysis and cell-surface level of
MT1-MMP
As reported for other cell types (Galvez et al., 2002; Sheikh et
al., 2000), both MT1-MMP and Endo180 are localised in a
punctate distribution at the surface of HT1080 cells and in
intracellular endosomes, particularly in the perinuclear region (Fig.
3A). Only limited colocalisation of MT1-MMP and Endo180 was
observed (Fig. 3A arrows). To address the mechanism by which
Endo180 expression influences MT1-MMP activity, we
investigated MT1-MMP expression and localisation following
Endo180 downregulation. Immunoblot analysis of whole-cell
lysates revealed a significant accumulation of the 43-45 kDa
autocatalytic MT1-MMP fragment in Endo180-depleted cells
(Fig. 3B,C), directly confirming increased MT1-MMP activity
(Lehti et al., 1998). However, the level of mature (~60 kDa) MT1-
MMP was unaffected by Endo180 downregulation, even in the
presence of GM6001 to prevent increased MT1-MMP autolysis
(Fig. 3C). Consistently, no change in MT1-MMP mRNA level was
detected (supplementary material Fig. S4; Klingbeil et al., 2009).
These data suggest that enhanced MT1-MMP activity and
proMMP-2 activation might be mediated by an increased
level of cell-surface-active MT1-MMP following Endo180
downregulation. To address this, cell-surface expression of MT1-
MMP was analysed by FACS using a mAb directed against the
MT1-MMP catalytic domain that recognises active (~60 kDa)
MT1-MMP but not the 44 kDa autolysis product (Galvez et al.,
2002). These experiments were performed in the presence of
GM6001 to facilitate detection of active MT1-MMP, independent
of increased autolysis. A significantly increased cell-surface level
of active MT1-MMP was observed following Endo180 depletion
(Fig. 3D), suggesting that Endo180 expression can regulate MT1-
MMP membrane localisation and consequent enzyme activity.
Regulation of MT1-MMP activity requires the collagen binding
and/or internalisation function of Endo180
Endo180 binds and internalises collagens in vitro (Engelholm et
al., 2003; Kjoller et al., 2004; Wienke et al., 2003) and native
collagens in vivo (Curino et al., 2005; Wagenaar-Miller et al.,
2007; Wienke et al., 2007). MT1-MMP activity and MMP-2
activation are induced by collagen in several cell types, including
HT1080 cells. Several mechanisms have been proposed to underlie
the collagen-mediated increase in MT1-MMP activity involving
both transcriptional and non-transcriptional pathways, including
increased cell-surface expression of MT1-MMP (Ellerbroek et al.,
1999; Lafleur et al., 2006; Maquoi et al., 2000; Ruangpanit et al.,
2001; Tam et al., 2002). This raised the possibility that the collagen
binding and/or internalisation function of Endo180 directly
underpins its ability to control MT1-MMP activity. Consequently,
we first confirmed that Endo180 in HT1080 cells, as in other cells,
functions to bind and internalise collagens (supplementary material
Fig. S5). Next, the turnover of collagen was investigated using a
Sircol assay, which detects collagen types I to V (Fineschi et al.,
Fig. 2. Loss of MT1-MMP reverses MMP-2 activation following Endo180
downregulation. (A)HT1080 cells were transfected with MT1-MMP or
control siRNAs, lysed 48 hours later and immunoblotted for MT1-MMP and
a-tubulin. (B,C)HT1080 cells transfected with Endo180 or MT1-MMP
control or targeting siRNA, alone or in combination, were cultured as in Fig.
1A-D. (B)Gelatin zymogram of conditioned media. (C)Active MMP-2 levels
were quantified as for Fig. 1B; **P<0.001 (n6).
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2006). As shown in Fig. 4A, increased collagen levels accumulated
in the conditioned media of Endo180-siRNA-treated cells
compared with control cells. These data are consistent with in
vivo studies where loss of Endo180 (Curino et al., 2005) or
expression of an internalisation-defective Endo180 mutant
(Wienke et al., 2007) led to increased tumour-associated collagens.
To determine whether misregulation of collagen turnover was
important for increased MT1-MMP activity, we used the collagen
synthesis inhibitor AzC (azetidine-2-carboxylic acid), a proline
analogue that incorporates into the collagen polypeptide but
cannot be hydroxylated (Maehata et al., 2006). AzC prevented
the increased collagen accumulation following Endo180
downregulation (Fig. 4B) and, importantly, inhibited both the
increased level of cell-surface active MT1-MMP and MMP-2
activation (Fig. 4C,D). This effect was specific, because MMP-2
activation in response to PMA (phorbol 12-myristate 13-acetate)
or concanavalin A (both known inducers of MT1-MMP-dependent
MMP-2 activation) was unaffected by AzC (Fig. 4E), as was PMA-
induced upregulation of proMMP-9 (Fig. 4E). Additionally, AzC
did not affect cell viability (supplementary material Table S2) or
the expression levels of non-collagenous proteins (supplementary
material Fig. S6).
To directly demonstrate that the mechanism by which Endo180
regulates MT1-MMP activity requires its collagen binding and/or
Fig. 3. Endo180 regulates MT1-MMP autolysis and
cell-surface levels. (A)HT1080 cells double-
immunostained for Endo180 and MT1-MMP. Scale
bar: 10mM. Arrows indicate colocalisation.
(B-D)Control- or Endo180-siRNA-transfected cells
were cultured as for Fig. 1A-D. (B)Lysates
immunoblotted for MT1-MMP. Arrows indicate
latent (immature ~63 kDa), active (mature ~60 kDa)
MT1-MMP and its autocatalytic product (43-46
kDa). Densitometric quantification of MT1-MMP
autocatalytic fragment normalised to a-tubulin.
(C)Cells as in B were untreated or treated with
GM6001 (5mM). Upper panel: lysates were
immunoblotted for MT1-MMP. Lower panel:
densitometric quantification of mature MT1-MMP +
GM6001 normalised to a-tubulin. (D)Cells as in B
were treated with GM6001 and analysed by FACS
for cell-surface Endo180 (mAb A5/158) and active
MT1-MMP (mAb LEM2/15.8). Lines represent:
control-siRNA-transfected cells (red), Endo180-
siRNA-transfected cells (green), irrelevant IgG
binding to control- and Endo180-siRNA-transfected
cells (black, grey respectively). The histogram shows
active MT1-MMP relative fluorescent intensity
calculated as the mean fluorescent intensity of test
Ab divided by mean fluorescent intensity of
irrelevant IgG and expressed as a percentage of
mock-transfected cells. **P<0.01 (n4).
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
4046
internalisation function, we performed a rescue experiment. Cells
transfected with siRNAs specific for target sequences in human
but not murine Endo180 were co-transfected with either murine
full-length Endo180, murine N-terminal-truncated Endo180
Journal of Cell Science 122 (22)
lacking the collagen-binding domain (East et al., 2003) or empty
vector (Fig. 4F). Importantly, expression in Endo180-siRNA-
treated cells of wild-type murine Endo180, but not the non-
collagen-binding Endo180 mutant, inhibited the collagen
Fig. 4. Regulation of MT1-MMP activity requires the collagen binding-and-uptake function of Endo180. (A)Collagen levels were analysed in conditioned media
from control- or Endo180-siRNA-transfected cells and expressed relative to levels from mock-transfected cells; mean + s.d. (n2). (B)Endo180-siRNA-transfected
cells were cultured with or without AzC, or alternatively were co-transfected with murine wild-type Endo180, N-terminal-truncated Endo180 (mutant) or vector.
The conditioned media were analysed for collagen; mean + s.d. relative to untreated Endo180-siRNA-transfected cells (n2). (C)siRNA-transfected cells as
indicated were cultured in the presence of GM6001 and with or without AzC for 48 hours and were analysed by FACS for active MT1-MMP (as for Fig. 3D). Data
presented are relative to mock-transfected cells for each treatment (n3). (D)Cells treated as for C in the absence of GM6001. Conditioned media were analysed
for MMP-2 activation and quantified as for Fig. 1F (n4). (E)Cells were cultured with or without AzC for 57 hours and then stimulated with concanavalin A
(25mg/ml) or PMA (100 nM) for 18 hours. The conditioned media were analysed for MMP-2 activation. (F-H)Cells were transfected with control or Endo180
siRNA plus either murine wild-type Endo180 (WT-Endo180), N-terminal-truncated Endo180 (Endo180Ex2-6) or vector and cultured with or without GM6001 as
above. (F)Lysates were immunoblotted for Endo180, FLAG epitope and a-tubulin. (G)Cells treated with GM6001 were analysed by FACS as for C; mean + s.d.
relative to mock-transfected cells (n2). (H)Conditioned media of cells in the absence of GM6001 were analysed and quantified for MMP-2 activation as for
Fig. 1F; mean + s.d. (n3).
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accumulation (Fig. 4B), the increased cell-surface level of active
MT1-MMP (Fig. 4G) and the activation of MMP-2 (Fig. 4H).
Conclusion
This study identifies a new role for Endo180 in the control of
pericellular proteolysis in HT1080 cells through negative regulation
of MT1-MMP activity and MMP-2 activation. The observation that
wild-type Endo180, and not a non-collagen-binding mutant, restores
the cell-surface-active MT1-MMP and MMP-2 activation to control
levels in Endo180-depleted cells directly demonstrates that Endo180
suppresses MT1-MMP activity and MMP-2 activation through a
mechanism that is dependent on its collagen binding and/or
internalisation function. Although we could robustly
immunoprecipitate both Endo180 and MT1-MMP, we were unable
to demonstrate a direct physical association between these two
receptors using reciprocal co-immunoprecipitation experiments
(not shown), suggesting that it is unlikely that Endo180 plays a
direct role in sequestering and/or clearance of MT1-MMP.
Together, these data support a model in which Endo180
expression promotes a local pericellular environment favouring
reduced collagen-induced MT1-MMP activity, suggesting that
Endo180 can act as a functional link between the two major
pathways of collagen remodelling. However, it remains possible
that uptake of collagen-associated components or Endo180-
mediated signalling might impact on the regulation of proteolysis.
Although MMP-2 levels in mammary tumours of wild-type and
Endo180–/– mice were found not to correlate with Endo180
expression, MMP-2 activation was not addressed (Curino et al.,
2005). Furthermore, these data were derived from whole-tumour
explants excised at a single time-point, potentially masking any
spatio-temporal differences in MT1-MMP activity.
The interplay between extracellular and specific intracellular
mechanisms of proteolysis demonstrated here might be important in
limiting indiscriminate matrix degradation and in coordinating the
balanced level of local proteolysis required for efficient cell migration.
Additionally, our data suggest that regulation of Endo180 expression
might either promote local pericellular proteolysis and release of
substrate degradation products, or act to preserve pericellular collagen
as a substrate for cell adhesion and survival. This might be important
where one collagen degradation pathway is spatially and/or temporally
favoured over the other, for example to control distinct cellular
behaviour; note that Endo180 is differentially expressed during early
and late stages of wound healing (Honardoust et al., 2006). Moreover,
Endo180 and MT1-MMP are required for collagen remodelling during
post-natal bone development (Wagenaar-Miller et al., 2007) and in
tumour progression (Curino et al., 2005; Wienke et al., 2007),
suggesting that functional interactions between these two pathways
might be important in physiological and pathological collagen
remodelling. Consequently, it will be important in future studies to
establish the relevance of these observations in other cell types and
in complex in vivo models involving physiological and pathological
collagen remodelling.
Materials and Methods
Reagents
Antibodies: anti-human MT1-MMP N175 (a gift of Gillian Murphy, CRUK,
Cambridge Research Institute, UK) recognises all forms of the MT1-MMP receptor
(d’Ortho et al., 1998); mAb LEM2/15.8 recognises the MT1-MMP catalytic domain
(Galvez et al., 2002); anti-transferrin receptor (B3/25); anti-Endo180 (A5/158) (Sheikh
et al., 2000); anti-TIMP-2 (T2-N IC3, Merck Biosciences); neutralising anti-uPA
(American Diagnostica); anti-a-tubulin (Sigma-Aldrich). Recombinant MMPs,
mutated stable human recombinant plasminogen activator inhibitor 1 (PAI-1),
amiloride and MMP inhibitor, GM6001 were all from Merck. Aprotinin, Spectrozyme
PL, human lys-plasminogen were from American Diagnostica. HT1080 cells (LGC
Promochem) were cultured in advanced DMEM containing 10% FBS. SiRNA
oligonucleotide sequences (Dharmacon) are detailed in supplementary material Table
S1. Murine Endo180 constructs were generated by PCR from cDNA isolated from
embryonic fibroblasts (East et al., 2003) using a 3 primer containing the FLAG
epitope. Amplified DNA was cloned into pcDNA3.1.
Cell treatments
HT1080 cells were transfected with siRNAs (20 nM) in serum-free opti-MEM using
Oligofectamine (Invitrogen), for 4 hours, then transferred to normal growth media.
At 24 hours post-transfection, media were exchanged for serum-free advanced
DMEM, collected 48 hours later, clarified and stored at –20°C. Cells were lysed
in Laemmli sample buffer or counted for cell viability. For collagen inhibition
experiments, cells were cultured with AzC for 16 hours before siRNA transfection
and for the remainder of the experiment. uPA inhibitors were added following siRNA
treatment for the duration of the experiment. To measure collagen production,
siRNA- or mock-transfected cells were transferred into advanced DMEM containing
0.1% FBS for up to 90 hours. For immunofluorescence, fixed and permeabilised
cells were double-stained for Endo180 and MT1-MMP using mAb A5/158 then
sheep polyclonal Ab N175, respectively, and Alexa-Fluor-conjugated secondary
Abs.
Gelatin zymography
Conditioned media or cell lysates from equal cell numbers, plus non-reducing
sample buffer, were subjected to zymography using 11% acrylamide gels co-
polymerised with 1.2 mg/ml gelatin. Gels renatured in 2.5% Triton X-100 (for 1
hour) were incubated overnight (48 hours for lysates) at 37°C in 50 mM Tris-HCl
buffer (pH 7.6), 200 mM NaCl, 5 mM CaCl2 and 0.06% Brij-35. Gels were stained
and de-stained in 0.025% Coomassie PhastGel Blue R in 30% methanol and 10%
acetic acid. For MMP-2, bands representing latent (72 kDa), intermediate (64 kDa)
and active (62 kDa) forms were quantified using Kodak image analysis software.
Plasminogen activator zymography
Conditioned media samples from equal cell numbers were mixed with non-reducing
sample buffer and electrophoresed on 11% acrylamide gels containing 1 mg/ml casein
and 13 mg/ml human plasminogen. Gels were subsequently treated as above.
Plasminogen activator activity
Conditioned media were tested for plasminogen activator activity using a Spectrolyse
urokinase activity assay (American Diagnostica) in 50 mM Tris-HCl buffer pH 7.4,
0.01% Tween 80, 6 mM 6-aminohexanoic acid and 0.1 mg/ml human Lys-
plasminogen. Reactions were initiated by 0.4 mM Spectrozyme PL, a chromogenic
substrate for plasmin. Absorbance (405 nm) was monitored in a SpectraMax Plus
384 plate reader (Molecular Devices). uPA activity (U/ml) was measured by reference
to a pure human uPA standard curve. Specificity was established by assaying
conditioned media from experiments including specific uPA inhibitors (Fig. 1E).
Collagen assay
Conditioned media from equal cell numbers were concentrated fivefold and analysed
for total collagen (types I-V) using a Sircol soluble collagen assay kit as described
(Biocolor Ltd) (Fineschi et al., 2006). Collagen was measured by reference to a type-
I collagen standard curve.
Statistics
Unless stated otherwise, data represent mean ± s.e.m. analysed by analysis of variance
(ANOVA) and Bonferroni multiple comparison test.
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